Inmune Bio, Inc. (INMB) › Shareholders' EquityInmune Bio, Inc. (INMB) — Shareholders' EquityAnnual figures by period end, from SEC filings.2016-12-31: -$149.2K2017-12-31: $18.10M2018-12-31: $16.54M2019-12-31: $23.61M2020-12-31: $38.75M2021-12-31: $80.22M2022-12-31: $60.10M2023-12-31: $37.34M2024-12-31: $32.10M2025-12-31: $23.52M$23.52M2016-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$23.52M-26.7%2026-03-30Balance as of period end2024-12-31$32.10M-14.0%2026-03-30Balance as of period end2023-12-31$37.34M-37.9%2026-03-30Balance as of period end2022-12-31$60.10M-25.1%2025-03-27Balance as of period end2021-12-31$80.22M+107.0%2024-03-28Balance as of period end2020-12-31$38.75M+64.1%2023-03-02Balance as of period end2019-12-31$23.61M+42.7%2022-03-03Balance as of period end2018-12-31$16.54M-8.6%2021-03-04Balance as of period end2017-12-31$18.10M—2020-03-11Balance as of period end2016-12-31-$149.2K—2019-03-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)